https://www.sciencedaily.com/news/health_medicine/cold_and_flu/ Latest medical research on cold and flu viruses, including symptoms, remedies, prevention and treatment. Learn how you can help protect yourself from cold and flu viruses, including swine flu and bird flu. en-us Wed, 15 Apr 2026 09:34:03 EDT Wed, 15 Apr 2026 09:34:03 EDT 60 https://www.sciencedaily.com/images/scidaily-logo-rss.png https://www.sciencedaily.com/news/health_medicine/cold_and_flu/ For more science news, visit ScienceDaily. https://www.sciencedaily.com/releases/2026/04/260411022027.htm A new nanodisc-based platform lets scientists study viral proteins in a form that closely mimics real viruses, revealing how antibodies truly recognize them. This approach uncovered hidden interactions in viruses like HIV and Ebola that traditional methods missed. By recreating the virus’s membrane environment, researchers can better understand how immune defenses work. The technique could speed up the development of more effective vaccines. Sun, 12 Apr 2026 06:42:12 EDT https://www.sciencedaily.com/releases/2026/04/260411022027.htm https://www.sciencedaily.com/releases/2026/03/260317015933.htm mRNA vaccines saved millions of lives during COVID-19 but have limitations like waning immunity and complex production. Scientists are now testing a new platform called DoriVac, which uses folded DNA nanostructures to better control how the immune system responds. In early studies, it produced strong antibody and T cell responses in both mice and human models. Researchers say it could lead to more stable, easier-to-manufacture vaccines for diseases like COVID-19, HIV, and Ebola. Tue, 17 Mar 2026 01:59:33 EDT https://www.sciencedaily.com/releases/2026/03/260317015933.htm https://www.sciencedaily.com/releases/2026/02/260222092258.htm Scientists at Stanford Medicine have unveiled a bold new kind of “universal” vaccine that could one day protect against everything from COVID-19 and the flu to bacterial pneumonia and even common allergens. Instead of targeting a specific virus or bacterium, the nasal spray vaccine supercharges the lungs’ own immune defenses, keeping them on high alert for months. In mice, it slashed viral levels, prevented severe illness, and even blocked allergic reactions. Mon, 23 Feb 2026 08:45:18 EST https://www.sciencedaily.com/releases/2026/02/260222092258.htm https://www.sciencedaily.com/releases/2026/02/260204114343.htm As bird flu continues to circulate in animals and spill over into humans, researchers are racing to stop it before it adapts to spread widely between people. A new nasal spray vaccine showed strong protection against H5N1 in animal tests, outperforming traditional flu shots. Because it targets the nose and lungs, it may prevent infection at the earliest stage. Wed, 04 Feb 2026 11:43:43 EST https://www.sciencedaily.com/releases/2026/02/260204114343.htm https://www.sciencedaily.com/releases/2026/01/260122074702.htm Scientists found that nasal cells act as a first line of defense against the common cold, working together to block rhinovirus soon after infection. A fast antiviral response can stop the virus before symptoms appear. If that response is weakened or delayed, the virus spreads and causes inflammation and breathing problems. The study highlights why the body’s reaction matters more than the virus alone. Thu, 22 Jan 2026 08:15:47 EST https://www.sciencedaily.com/releases/2026/01/260122074702.htm https://www.sciencedaily.com/releases/2026/01/260118115058.htm While social media continues to circulate claims linking acetaminophen to autism in children, medical experts say those fears distract from a far more serious and proven danger: overdose. Acetaminophen, found in Tylenol and many cold and flu remedies, is one of the leading causes of emergency room visits, hospitalizations, and acute liver failure in the United States. Sun, 18 Jan 2026 12:03:01 EST https://www.sciencedaily.com/releases/2026/01/260118115058.htm https://www.sciencedaily.com/releases/2026/01/260110211204.htm In a striking real-world experiment, flu patients spent days indoors with healthy volunteers, but the virus never spread. Researchers found that limited coughing and well-mixed indoor air kept virus levels low, even with close contact. Age may have helped too, since middle-aged adults are less likely to catch the flu than younger people. The results highlight ventilation, air movement, and masks as key defenses against infection. Sun, 11 Jan 2026 02:45:57 EST https://www.sciencedaily.com/releases/2026/01/260110211204.htm https://www.sciencedaily.com/releases/2026/01/260107225532.htm Long COVID affects an estimated 65 million people worldwide and can damage the brain, heart, blood vessels, and immune system long after infection. Researchers now link symptoms to lingering virus, inflammation, micro-clots, and disrupted energy metabolism. While structured rehab and pacing can improve quality of life, a growing list of experimental treatments—from antivirals and metformin to microbiome therapies and biologics—shows early promise. Clear answers, however, are still limited by small studies and the lack of large, definitive trials. Thu, 08 Jan 2026 19:57:41 EST https://www.sciencedaily.com/releases/2026/01/260107225532.htm https://www.sciencedaily.com/releases/2026/01/260105165818.htm A long-running debate over Tamiflu’s safety in children may finally be settled. Researchers found that influenza, not the antiviral medication, was linked to serious neuropsychiatric events like seizures and hallucinations. Even more striking, kids treated with Tamiflu had about half the risk of these events compared to untreated children with the flu. The results suggest the drug may be protective rather than harmful. Mon, 05 Jan 2026 20:48:09 EST https://www.sciencedaily.com/releases/2026/01/260105165818.htm https://www.sciencedaily.com/releases/2025/12/251204024226.htm Scientists have captured a never-before-seen, high-resolution look at influenza’s stealthy invasion of human cells, revealing that the cells aren’t just helpless victims. Using a groundbreaking imaging technique, researchers discovered that our cells actually reach out and “grab” the virus as it searches for the perfect entry point, surfing along the membrane. Thu, 04 Dec 2025 03:46:07 EST https://www.sciencedaily.com/releases/2025/12/251204024226.htm https://www.sciencedaily.com/releases/2025/12/251203004721.htm A unique vaccine rollout in Wales gave researchers an accidental natural experiment that revealed a striking reduction in dementia among seniors who received the shingles vaccine. The protective effect held steady across multiple analyses and was even stronger in women. Evidence also suggests benefits for people who already have dementia, hinting at a therapeutic effect. Wed, 03 Dec 2025 10:22:27 EST https://www.sciencedaily.com/releases/2025/12/251203004721.htm https://www.sciencedaily.com/releases/2025/11/251128050503.htm Researchers discovered why bird flu can survive temperatures that stop human flu in its tracks. A key gene, PB1, gives avian viruses the ability to replicate even at fever-level heat. Mice experiments confirmed that fever cripples human-origin flu but not avian strains, especially those with avian-like PB1. These findings highlight how gene swapping could fuel future pandemics. Fri, 28 Nov 2025 07:37:38 EST https://www.sciencedaily.com/releases/2025/11/251128050503.htm https://www.sciencedaily.com/releases/2025/11/251108012853.htm New research suggests the COVID-19 vaccine could help children with eczema stay healthier overall. Vaccinated kids had lower rates of infections and allergies, including asthma and rhinitis, compared with unvaccinated peers. Experts believe the vaccine may help prevent allergic conditions from worsening, showing its value beyond protection from COVID-19. Sat, 08 Nov 2025 04:23:03 EST https://www.sciencedaily.com/releases/2025/11/251108012853.htm https://www.sciencedaily.com/releases/2025/10/251027224837.htm Researchers found that COVID-19 mRNA vaccines significantly increased survival in lung and skin cancer patients undergoing immunotherapy. The vaccine appears to prime the immune system in a powerful, nonspecific way, enhancing cancer treatment outcomes. If confirmed, the discovery could lead to a universal cancer vaccine and transform oncology care. Tue, 28 Oct 2025 09:47:26 EDT https://www.sciencedaily.com/releases/2025/10/251027224837.htm https://www.sciencedaily.com/releases/2025/10/251019120503.htm A groundbreaking study reveals that cancer patients who received a COVID-19 mRNA vaccine within 100 days of starting immunotherapy lived dramatically longer than those who didn’t. Researchers from the University of Florida and MD Anderson Cancer Center discovered that the vaccine’s immune-activating properties may boost cancer-fighting responses, acting like a nonspecific “flare” that reawakens the immune system. Sun, 19 Oct 2025 12:43:31 EDT https://www.sciencedaily.com/releases/2025/10/251019120503.htm https://www.sciencedaily.com/releases/2025/09/250917221001.htm Why do some people stay protected after vaccination while others quickly lose immunity? Researchers in Japan tracked over 2,500 people for 18 months and found four distinct immune response patterns. The so-called “rapid-decliners” looked strong at first but lost antibodies quickly, leaving them more vulnerable to infection. Thu, 18 Sep 2025 09:00:27 EDT https://www.sciencedaily.com/releases/2025/09/250917221001.htm https://www.sciencedaily.com/releases/2025/09/250907172649.htm Scientists have uncovered a surprising new pathway behind life-threatening food allergies. Instead of histamine, a different chemical called leukotrienes drives severe reactions in the gut. These molecules, released by specialized mast cells, trigger inflammation and anaphylaxis when food allergens are ingested. Drugs already approved for asthma may block this pathway, opening the door to new ways to prevent or treat food-induced allergic emergencies. Mon, 08 Sep 2025 04:48:45 EDT https://www.sciencedaily.com/releases/2025/09/250907172649.htm https://www.sciencedaily.com/releases/2025/09/250901104649.htm Japanese scientists have developed ADRIANA, a non-opioid painkiller that could provide powerful relief without the dangers of addiction. With successful trials already completed, large U.S. studies are now underway, raising hopes for a safer future in pain treatment. Tue, 02 Sep 2025 03:32:58 EDT https://www.sciencedaily.com/releases/2025/09/250901104649.htm https://www.sciencedaily.com/releases/2025/08/250827010734.htm Researchers propose that the U.S. could safely drop adult tetanus and diphtheria boosters, saving $1 billion annually, since childhood vaccinations provide decades of protection. Evidence from the U.K. shows that skipping boosters has not led to higher disease rates. Wed, 27 Aug 2025 11:16:28 EDT https://www.sciencedaily.com/releases/2025/08/250827010734.htm https://www.sciencedaily.com/releases/2025/08/250826005217.htm A nationwide study found that recent colds caused by rhinoviruses can give short-term protection against COVID-19. Children benefit most, as their immune systems react strongly with antiviral defenses, helping explain their lower rates of severe illness. Tue, 26 Aug 2025 04:54:56 EDT https://www.sciencedaily.com/releases/2025/08/250826005217.htm https://www.sciencedaily.com/releases/2025/08/250818102951.htm A breakthrough mRNA cancer vaccine has shown the ability to supercharge the effects of immunotherapy in mice, sparking hope for a universal “off-the-shelf” treatment that could fight multiple cancers. Unlike traditional vaccines designed to target specific tumor proteins, this approach simply revs up the immune system as if it were fighting a virus. The results were dramatic—when paired with checkpoint inhibitors, tumors shrank, and in some cases, the vaccine alone wiped them out. Tue, 19 Aug 2025 02:22:25 EDT https://www.sciencedaily.com/releases/2025/08/250818102951.htm https://www.sciencedaily.com/releases/2025/08/250803011820.htm Scientists have discovered that flossing between your teeth could one day help vaccinate you. By targeting a uniquely permeable gum tissue called the junctional epithelium, this new method stimulates immunity right where many infections enter: the mouth, nose, and lungs. Using dental floss on mice to apply a flu vaccine triggered a robust immune response—better than existing oral approaches and comparable to nasal vaccines, but without the risks. It even worked with mRNA and protein-based vaccines. Sun, 03 Aug 2025 03:57:21 EDT https://www.sciencedaily.com/releases/2025/08/250803011820.htm https://www.sciencedaily.com/releases/2025/07/250724040508.htm Scientists in Switzerland have cracked open a century-old viral mystery by decoding the genome of the 1918 influenza virus from a preserved Zurich patient. This ancient RNA revealed that the virus had already adapted to humans at the very start of the pandemic, carrying mutations that made it both more infectious and more immune-resistant. By pioneering a new method to recover fragile RNA from preserved tissue, researchers gained rare insights into how flu viruses evolve. The study not only revives the history of one of humanity's deadliest outbreaks but also arms us with critical knowledge to face future pandemics with smarter, science-based strategies. Thu, 24 Jul 2025 12:13:19 EDT https://www.sciencedaily.com/releases/2025/07/250724040508.htm https://www.sciencedaily.com/releases/2025/07/250723045708.htm HIV antivirals may be the key to stopping HTLV-1, a deadly virus with no cure. In a decade-long study, researchers successfully suppressed the virus in mice and discovered a way to kill infected cells, offering hope for the first preventative and curative treatments. Thu, 24 Jul 2025 00:51:03 EDT https://www.sciencedaily.com/releases/2025/07/250723045708.htm https://www.sciencedaily.com/releases/2025/07/250720034025.htm A new UK study shows that vaccinating pregnant women against RSV has led to a staggering 72% drop in hospitalizations of newborns with severe lung infections. By passing virus-fighting antibodies to their babies, vaccinated mothers are helping shield infants during their most vulnerable early months. Mon, 21 Jul 2025 08:38:35 EDT https://www.sciencedaily.com/releases/2025/07/250720034025.htm https://www.sciencedaily.com/releases/2025/07/250704032925.htm A promising path to fighting COVID and other coronaviruses may have been based on a serious mistake. Scientists had zeroed in on a part of the virus called the NiRAN domain, believed to be a powerful target for new antiviral drugs. But when a Rockefeller team revisited a highly cited 2022 study, they found the evidence didn’t hold up. Key molecules shown in the original virus model were actually missing. Their discovery could help prevent wasted time and resources in the race to develop better treatments—and highlights how even one bad blueprint can throw off years of research. Fri, 04 Jul 2025 08:28:05 EDT https://www.sciencedaily.com/releases/2025/07/250704032925.htm https://www.sciencedaily.com/releases/2025/06/250603114634.htm A new study shows how person-to-person variation in antibody immunity plays a key role in shaping which influenza (flu) strains dominate in a population. Tue, 03 Jun 2025 11:46:34 EDT https://www.sciencedaily.com/releases/2025/06/250603114634.htm https://www.sciencedaily.com/releases/2025/05/250515145628.htm A decades-long scientific challenge in HIV vaccine development has been finding a way to train the immune system to produce antibodies that can target many variants of the virus. Traditional approaches haven't worked -- largely because HIV mutates rapidly and hides key parts of itself from the immune system. Now, a new study combining data from two separate phase 1 clinical trials shows that a targeted vaccine strategy can successfully activate early immune responses relevant to HIV, and, in one trial, further advance them -- a key step toward a long-sought goal in vaccine development. Thu, 15 May 2025 14:56:28 EDT https://www.sciencedaily.com/releases/2025/05/250515145628.htm https://www.sciencedaily.com/releases/2025/05/250514181250.htm Most vaccines -- and boosters -- are injected directly into muscle tissue, usually in the upper arm, to kickstart the body's immune system in the fight against disease. But for respiratory diseases like COVID-19, it can be important to have protection right where the virus enters: the respiratory tract. In a new study, researchers found that nasal vaccine boosters can trigger strong immune defenses in the respiratory tract, even without the help of immune-boosting ingredients known as adjuvants. The findings, researchers suggest, may offer critical insights into developing safer, more effective nasal vaccines in the future. Wed, 14 May 2025 18:12:50 EDT https://www.sciencedaily.com/releases/2025/05/250514181250.htm https://www.sciencedaily.com/releases/2025/05/250509122258.htm A research team has achieved a significant breakthrough in developing broadly protective, live-attenuated influenza vaccines (LAIV). These innovative LAIV platforms offer potential to develop universal influenza vaccines that induce a more robust immune response against various virus subtypes, including both human and avian strains. Fri, 09 May 2025 12:22:58 EDT https://www.sciencedaily.com/releases/2025/05/250509122258.htm https://www.sciencedaily.com/releases/2025/05/250508112429.htm Scientists have engineered a monoclonal antibody that can protect mice from a lethal dose of influenza A, a new study shows. The new molecule combines the specificity of a mature flu fighter with the broad binding capacity of a more general immune system defender. Thu, 08 May 2025 11:24:29 EDT https://www.sciencedaily.com/releases/2025/05/250508112429.htm https://www.sciencedaily.com/releases/2025/05/250508112314.htm Researchers have developed EVE-Vax, an AI tool that forecasts viral mutations and designs test proteins to guide next-generation vaccines. The breakthrough could allow scientists to build vaccines that stay ahead of fast-changing threats like COVID-19 and influenza. Thu, 08 May 2025 11:23:14 EDT https://www.sciencedaily.com/releases/2025/05/250508112314.htm https://www.sciencedaily.com/releases/2025/05/250507170530.htm Scientists have uncovered a promising new way to enhance the effectiveness of vaccines by tapping into the potential of a specific type of immune cell, opening the door to long-lasting vaccines for viruses and enhanced cancer therapies. The study used a novel approach combined with cutting-edge mRNA vaccine technology to increase the formation of a type of T cell which has remarkable self-renewing capacity and can remember threats for years and even decades. Wed, 07 May 2025 17:05:30 EDT https://www.sciencedaily.com/releases/2025/05/250507170530.htm https://www.sciencedaily.com/releases/2025/05/250507130605.htm Influenza viruses are among the most likely triggers of future pandemics. A research team has developed a method that can be used to study the interaction of viruses with host cells in unprecedented detail. With the help of their new development, they have also analyzed how novel influenza viruses use alternative receptors to enter target cells. Wed, 07 May 2025 13:06:05 EDT https://www.sciencedaily.com/releases/2025/05/250507130605.htm https://www.sciencedaily.com/releases/2025/05/250505204912.htm People who are given a vaccine for shingles have a 23% lower risk of cardiovascular events, including stroke, heart failure, and coronary heart disease, according to a recent study of more than a million people. The protective effect of the vaccine lasts for up to eight years and is particularly pronounced for men, people under the age of 60 and those with unhealthy lifestyles. Mon, 05 May 2025 20:49:12 EDT https://www.sciencedaily.com/releases/2025/05/250505204912.htm https://www.sciencedaily.com/releases/2025/04/250423164249.htm Researchers hope to launch human clinical trials in their quest for a vaccine to prevent the buildup of pathological tau after demonstrating that this vaccine generated a robust immune response in both mice and non-human primates. Wed, 23 Apr 2025 16:42:49 EDT https://www.sciencedaily.com/releases/2025/04/250423164249.htm https://www.sciencedaily.com/releases/2025/04/250422131245.htm A multi-state study reveals that many high-risk adults diagnosed with influenza (flu) in emergency departments and urgent care centers are not receiving timely antiviral treatment. Researchers found that only slightly more than half of these patients received antiviral prescriptions, and of those, only 80 percent were filled. This gap in treatment could increase the risk of severe flu complications, particularly for older adults and those with underlying conditions. Tue, 22 Apr 2025 13:12:45 EDT https://www.sciencedaily.com/releases/2025/04/250422131245.htm https://www.sciencedaily.com/releases/2025/04/250417145009.htm A vaccine under development has demonstrated complete protection in mice against a deadly variant of the virus that causes bird flu. The work focuses on the H5N1 variant known as 2.3.4.4b, which has caused widespread outbreaks in wild birds and poultry and other mammals. The vaccine is step toward more potent, versatile and easy-to-produce vaccines that public health officials believe will be needed to counteract evolving bird flu strains that grow resistant to existing vaccines. Thu, 17 Apr 2025 14:50:09 EDT https://www.sciencedaily.com/releases/2025/04/250417145009.htm https://www.sciencedaily.com/releases/2025/04/250409212523.htm A new study has found that certain bacteria living in the nose may influence how likely someone is to get a COVID-19 infection. The research reveals that certain types of nasal bacteria can affect the levels of key proteins the virus needs to enter human cells, offering new insight into why some people are more vulnerable to COVID-19 than others. Wed, 09 Apr 2025 21:25:23 EDT https://www.sciencedaily.com/releases/2025/04/250409212523.htm https://www.sciencedaily.com/releases/2025/04/250408122112.htm Scientists have pioneered an influenza virus vector-based nasal spray vaccine platform and developed a nasal spray H5N1 avian influenza vaccine. During the early COVID-19 pandemic, this platform enabled the rapid development of a nasal spray vaccine in collaboration with mainland China's Wantai BioPharm. After completing Phase 1-3 clinical trials, it was approved in 2022 as the world's first nasal spray COVID-19 vaccine. Tue, 08 Apr 2025 12:21:12 EDT https://www.sciencedaily.com/releases/2025/04/250408122112.htm https://www.sciencedaily.com/releases/2025/04/250408121657.htm Researchers have shown that differences in the entire rotavirus genome -- not just its two surface proteins -- affect how well vaccines work, helping to explain why some strains are more likely to infect vaccinated individuals. Tue, 08 Apr 2025 12:16:57 EDT https://www.sciencedaily.com/releases/2025/04/250408121657.htm https://www.sciencedaily.com/releases/2025/04/250404201407.htm Low vaccination rates for influenza viruses and the lack of an HSV vaccine underscore the need for a new approach to reduce viral transmission. Researchers have now used a clinical-grade antiviral chewing gum to substantially reduce viral loads of two herpes simplex viruses and two influenza A strains in experimental models. Fri, 04 Apr 2025 20:14:07 EDT https://www.sciencedaily.com/releases/2025/04/250404201407.htm https://www.sciencedaily.com/releases/2025/04/250403122940.htm A new CT-scan based risk score facilitates the identification of patients at risk of revision endoscopic sinus surgery due to chronic rhinosinusitis. Thu, 03 Apr 2025 12:29:40 EDT https://www.sciencedaily.com/releases/2025/04/250403122940.htm https://www.sciencedaily.com/releases/2025/04/250402122149.htm A unique vaccination rollout in Wales offered researchers a natural experiment: some older adults qualified for the shingles vaccine, while others just missed the cutoff. The results were striking — those who got the shot had a 20% lower risk of developing dementia within seven years. This breakthrough hints that viruses lurking in the nervous system may contribute to dementia and that prevention could be simpler than anyone imagined. Wed, 02 Apr 2025 12:21:49 EDT https://www.sciencedaily.com/releases/2025/04/250402122149.htm https://www.sciencedaily.com/releases/2025/03/250325141538.htm This research comes as many mosquito-borne viruses are spreading rapidly. Tue, 25 Mar 2025 14:15:38 EDT https://www.sciencedaily.com/releases/2025/03/250325141538.htm https://www.sciencedaily.com/releases/2025/03/250319143643.htm A study has found that a single dose of the Imvanex vaccine provides protection against Mpox with 84% effectiveness. For people with HIV, however, a single dose of the vaccine fails to offer sufficient protection. All at-risk groups, and people with HIV in particular, should therefore receive the second dose of the vaccine as recommended. Wed, 19 Mar 2025 14:36:43 EDT https://www.sciencedaily.com/releases/2025/03/250319143643.htm https://www.sciencedaily.com/releases/2025/03/250317184329.htm Existing antivirals may be less effective against this H5N1 bird flu strain, and prevention measures, such as avoiding raw milk consumption and reducing exposure in dairy workers, may be the most effective way to protect against the virus. Mon, 17 Mar 2025 18:43:29 EDT https://www.sciencedaily.com/releases/2025/03/250317184329.htm https://www.sciencedaily.com/releases/2025/03/250313180452.htm Older adults who were exposed to seasonal flu viruses that circulated prior to 1968 are more likely to have some protection against H5N1, and children would benefit more from H5N1 vaccines. Thu, 13 Mar 2025 18:04:52 EDT https://www.sciencedaily.com/releases/2025/03/250313180452.htm https://www.sciencedaily.com/releases/2025/03/250312134635.htm Researchers helped conduct an important new global health study that found a vaccine that protects against five strains of meningitis prevalent in sub-Saharan Africa is safe and effective for use in young children beginning at 9 months of age. This study provided evidence that formed the basis for the World Health Organization's (WHO) decision last year to recommend the pentavalent Men5CV meningitis vaccine for infants ages 9 months and older. Wed, 12 Mar 2025 13:46:35 EDT https://www.sciencedaily.com/releases/2025/03/250312134635.htm https://www.sciencedaily.com/releases/2025/03/250307125723.htm Recent outbreaks of highly pathogenic avian influenza (also known as bird flu) have created a need for rapid and sensitive detection methods to mitigate its spread. Now, researchers have developed a prototype sensor that detects a type of influenza virus that causes bird flu (H5N1) in air samples. The low-cost handheld sensor detects the virus at levels below an infectious dose and could lead to rapid aerosol testing for airborne avian influenza. Fri, 07 Mar 2025 12:57:23 EST https://www.sciencedaily.com/releases/2025/03/250307125723.htm https://www.sciencedaily.com/releases/2025/03/250306121242.htm Researchers have discovered how antibodies help to protect against contagious bacterial infections caused by Strep A, including strep throat. And the findings are already contributing to efforts to accelerate the development of a Strep A vaccine. Thu, 06 Mar 2025 12:12:42 EST https://www.sciencedaily.com/releases/2025/03/250306121242.htm https://www.sciencedaily.com/releases/2025/03/250305135134.htm A live-attenuated tuberculosis (TB) vaccine candidate in development elicits a much more balanced and effective immune response compared to the existing vaccine used across much of the world, according to preclinical research. Wed, 05 Mar 2025 13:51:34 EST https://www.sciencedaily.com/releases/2025/03/250305135134.htm https://www.sciencedaily.com/releases/2025/03/250303141305.htm As highly pathogenic H5N1 avian influenza continues to spread in the U.S., posing serious threats to dairy and poultry farms, both farmers and public health experts need better ways to monitor for infections, in real time, to mitigate and respond to outbreaks. Newly devised virus trackers can monitor for airborne particles of H5N1. Mon, 03 Mar 2025 14:13:05 EST https://www.sciencedaily.com/releases/2025/03/250303141305.htm https://www.sciencedaily.com/releases/2025/02/250226175926.htm Pre-existing immunity against seasonal H1N1 flu might help explain why most reported human cases of H5N1 bird flu in the U.S. have not resulted in lethal outcomes. Wed, 26 Feb 2025 17:59:26 EST https://www.sciencedaily.com/releases/2025/02/250226175926.htm https://www.sciencedaily.com/releases/2025/02/250224143249.htm This research comes as dengue-carrying mosquitoes expand their territory into new regions, including Southern California. Mon, 24 Feb 2025 14:32:49 EST https://www.sciencedaily.com/releases/2025/02/250224143249.htm https://www.sciencedaily.com/releases/2025/02/250224122956.htm Knowing where, when and for how long mallard ducks -- natural carriers of avian influenza -- stop and rest as they migrate can help predict the probability that they will spread bird flu to backyard poultry flocks, according to a new study. Mon, 24 Feb 2025 12:29:56 EST https://www.sciencedaily.com/releases/2025/02/250224122956.htm https://www.sciencedaily.com/releases/2025/02/250220123051.htm A new vaccine that boosts immunity against tuberculosis (TB) has been shown to be effective in pioneering pre-clinical trials. Thu, 20 Feb 2025 12:30:51 EST https://www.sciencedaily.com/releases/2025/02/250220123051.htm https://www.sciencedaily.com/releases/2025/02/250220122512.htm In their effort to answer a decades-old biological question about how the hepatitis B virus (HBV) is able to establish infection of liver cells, researchers have identified a vulnerability that opens the door to new treatments. Thu, 20 Feb 2025 12:25:12 EST https://www.sciencedaily.com/releases/2025/02/250220122512.htm https://www.sciencedaily.com/releases/2025/02/250218114037.htm Viruses, like those that cause COVID-19 or HIV, are formidable opponents once they invade our bodies. Antiviral treatments strive to block a virus or halt its replication. However, viruses are dynamic -- constantly evolving and changing shape, which can make designing antiviral treatments a challenge. Tue, 18 Feb 2025 11:40:37 EST https://www.sciencedaily.com/releases/2025/02/250218114037.htm https://www.sciencedaily.com/releases/2025/02/250205130931.htm Researchers report that all nine patients in a clinical trial being treated for stage III or IV clear cell renal cell carcinoma (a form of kidney cancer), generated a successful anti-cancer immune response after initiation of a personalized cancer vaccine. Wed, 05 Feb 2025 13:09:31 EST https://www.sciencedaily.com/releases/2025/02/250205130931.htm